Cargando…
Overview of Molecular Detection Technologies for MET in Lung Cancer
SIMPLE SUMMARY: A variety of MET aberrations that lead to the dysregulation of the MET oncogene and thus the activation of various signaling pathways have been described. These include MET overexpression, the activation of MET mutations comprising exon 14 skipping mutations, MET gene amplifications,...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251963/ https://www.ncbi.nlm.nih.gov/pubmed/37296895 http://dx.doi.org/10.3390/cancers15112932 |
_version_ | 1785056057558564864 |
---|---|
author | Heydt, Carina Ihle, Michaela Angelika Merkelbach-Bruse, Sabine |
author_facet | Heydt, Carina Ihle, Michaela Angelika Merkelbach-Bruse, Sabine |
author_sort | Heydt, Carina |
collection | PubMed |
description | SIMPLE SUMMARY: A variety of MET aberrations that lead to the dysregulation of the MET oncogene and thus the activation of various signaling pathways have been described. These include MET overexpression, the activation of MET mutations comprising exon 14 skipping mutations, MET gene amplifications, and MET fusions. Patients with such aberrations can be treated using a targeted inhibitor such as crizotinib, cabozantinib, tepotinib, and capmatinib. Therefore, the implementation of high-quality and sensitive methods for the detection of the various MET aberrations is essential. ABSTRACT: MET tyrosine kinase receptor pathway activation has become an important actionable target in solid tumors. Aberrations in the MET proto-oncogene, including MET overexpression, the activation of MET mutations, MET mutations that lead to MET exon 14 skipping, MET gene amplifications, and MET fusions, are known to be primary and secondary oncogenic drivers in cancer; these aberrations have evolved as predictive biomarkers in clinical diagnostics. Thus, the detection of all known MET aberrations in daily clinical care is essential. In this review, current molecular technologies for the detection of the different MET aberrations are highlighted, including the benefits and drawbacks. In the future, another focus will be on the standardization of detection technologies for the delivery of reliable, quick, and affordable tests in clinical molecular diagnostics. |
format | Online Article Text |
id | pubmed-10251963 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102519632023-06-10 Overview of Molecular Detection Technologies for MET in Lung Cancer Heydt, Carina Ihle, Michaela Angelika Merkelbach-Bruse, Sabine Cancers (Basel) Review SIMPLE SUMMARY: A variety of MET aberrations that lead to the dysregulation of the MET oncogene and thus the activation of various signaling pathways have been described. These include MET overexpression, the activation of MET mutations comprising exon 14 skipping mutations, MET gene amplifications, and MET fusions. Patients with such aberrations can be treated using a targeted inhibitor such as crizotinib, cabozantinib, tepotinib, and capmatinib. Therefore, the implementation of high-quality and sensitive methods for the detection of the various MET aberrations is essential. ABSTRACT: MET tyrosine kinase receptor pathway activation has become an important actionable target in solid tumors. Aberrations in the MET proto-oncogene, including MET overexpression, the activation of MET mutations, MET mutations that lead to MET exon 14 skipping, MET gene amplifications, and MET fusions, are known to be primary and secondary oncogenic drivers in cancer; these aberrations have evolved as predictive biomarkers in clinical diagnostics. Thus, the detection of all known MET aberrations in daily clinical care is essential. In this review, current molecular technologies for the detection of the different MET aberrations are highlighted, including the benefits and drawbacks. In the future, another focus will be on the standardization of detection technologies for the delivery of reliable, quick, and affordable tests in clinical molecular diagnostics. MDPI 2023-05-26 /pmc/articles/PMC10251963/ /pubmed/37296895 http://dx.doi.org/10.3390/cancers15112932 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Heydt, Carina Ihle, Michaela Angelika Merkelbach-Bruse, Sabine Overview of Molecular Detection Technologies for MET in Lung Cancer |
title | Overview of Molecular Detection Technologies for MET in Lung Cancer |
title_full | Overview of Molecular Detection Technologies for MET in Lung Cancer |
title_fullStr | Overview of Molecular Detection Technologies for MET in Lung Cancer |
title_full_unstemmed | Overview of Molecular Detection Technologies for MET in Lung Cancer |
title_short | Overview of Molecular Detection Technologies for MET in Lung Cancer |
title_sort | overview of molecular detection technologies for met in lung cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251963/ https://www.ncbi.nlm.nih.gov/pubmed/37296895 http://dx.doi.org/10.3390/cancers15112932 |
work_keys_str_mv | AT heydtcarina overviewofmoleculardetectiontechnologiesformetinlungcancer AT ihlemichaelaangelika overviewofmoleculardetectiontechnologiesformetinlungcancer AT merkelbachbrusesabine overviewofmoleculardetectiontechnologiesformetinlungcancer |